Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Chronix Biomedical has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners and 4 distinct art units, showing broad distribution across examination personnel and art-unit practices.
WILDER, CYNTHIA B is the busiest examiner and handles 1 pending matter. Effective management will require centralized tracking alongside responses tailored to the separate examination channels.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §102 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILDER, CYNTHIA B | 1 | 70.8% | +27.0% |
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
| ZHANG, KAIJIANG | 1 | 77.2% | +34.3% |
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.5% | +53.8% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17888353 | PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | PHAM, KHAI QUYNH TIEN | — |
| 17850889 | BREAST CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | ZHANG, KAIJIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17503056 | DETECTION AND QUANTIFICATION OF DONOR CELL-FREE DNA IN THE CIRCULATION OF ORGAN TRANSPLANT RECIPIENTS | KAPUSHOC, STEPHEN THOMAS | 107d overdue |
| 16284963 | PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | SITTON, JEHANNE SOUAYA | 44d overdue |
| 17914933 | METHODS FOR PRECISE AND BIAS-FREE QUANTIFICATION OF CELL-FREE DNA | WILDER, CYNTHIA B | — |
| 17850889 | BREAST CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | ZHANG, KAIJIANG | — |
| Art Unit | Apps |
|---|---|
| 1684 | 2 |
| 1681 | 1 |
| 1683 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17914933 | METHODS FOR PRECISE AND BIAS-FREE QUANTIFICATION OF CELL-FREE DNA | WILDER, CYNTHIA B | 1681 | §102 | Final Rejection | — | Pending | Sep 27, 2022 |
| 17888353 | PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | PHAM, KHAI QUYNH TIEN | 1684 | §101§112Other | Non-Final OA | — | Pending | Aug 15, 2022 |
| 17850889 | BREAST CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | ZHANG, KAIJIANG | 1684 | §102§112 | Non-Final OA | — | Pending | Jun 27, 2022 |
| 17503056 | DETECTION AND QUANTIFICATION OF DONOR CELL-FREE DNA IN THE CIRCULATION OF ORGAN TRANSPLANT RECIPIENTS | KAPUSHOC, STEPHEN THOMAS | 1683 | §103§112DP | Final Rejection | 107d overdue | Pending | Oct 15, 2021 |
| 16284963 | PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | SITTON, JEHANNE SOUAYA | 1682 | §112DP | Non-Final OA | 44d overdue | Pending | Feb 25, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChronix Biomedical has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Cynthia B Wilder has the most, with 1 of Chronix Biomedical's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
